Schivo Acquires Supreme Screw Products – Strengthens Position as a Leader in Medical and Life Sciences Technologies

February 8, 2021

Schivo notes Supreme Screw Products, Inc. is a leading supplier of precision machining, laser processing, and assembly services for the medical device market.

Since its founding in 1963, SSP has achieved consistent growth by providing novel engineering solutions to complex customer requirements, coupled with an innate focus on customer experience and timely service. SSP is led by Misha Migdal, President and CEO and operates out of two facilities in Plainview, New York.

“Misha and the Supreme team have established a great reputation in the industry by partnering with customers to address complex engineering challenges and providing innovative manufacturing processes. I am delighted to welcome Misha Migdal and the Supreme team to the Schivo family.” said Graham Reeves, CEO of Schivo. “Culturally, we both share a passion to serve customers with pioneering technologies coupled with exceptional quality and service. Additionally, the recent investment in an impressive additional 30,000 square foot facility highlights SSP’s commitment to their employees and customers and provides a great venue to serve our expanding business needs”.

“The SSP team and I look forward to joining Schivo. This union expands our ability to provide sophisticated precision components and assemblies to innovative medical OEMs around the world. Schivo and SSP together have capabilities unmatched in the medical device supply chain. We look forward to building a truly remarkable company with Graham and all the Schivo team”, said Misha Migdal, Supreme’s President.

This acquisition will strengthen Schivo’s development and manufacturing footprint, enhance its technical capabilities, and deepen customer partnerships. SSP’s two manufacturing facilities in Plainview, New York will be added to Schivo’s footprint in Ireland. SSP will complement Schivo’s existing capabilities for minimally invasive surgery and life sciences markets through the addition of micro-machining, laser processing, and assembly technologies. Customers will benefit from working with a single proven partner, offering a wider set of solutions, capable of serving their needs both globally and locally.

SourceSchivo

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”